FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385877462> ?p ?o ?g. }

• W4385877462 abstract "<p>ICOS agonist mAbs demonstrate single-agent antitumor activity. <b>A–C,</b> EMT6 (subcutaneous) tumor-bearing BALB/c mice were administered intraperitoneally biweekly with anti-mouse ICOS mAb [7E.17G9 (mIgG1)] or isotype control (mIgG1) for a total of six doses and evaluated for tumor growth (<b>A</b>), survival (<b>B</b>), and pharmacodynamic changes (<b>C</b>) within tumors. Each line in A represents an individual mouse (<i>n</i> = 10/group). Number of tumor-free mice at study termination are indicated within each subpanel. <b>B,</b> Kaplan–Meier plot illustrating OS in A. <b>C,</b> Percentage of tumor-infiltrating CD8⁺ T cells, T_reg cells, and associated CD8:T_reg cell ratio 48 hours after the third dose of anti-ICOS mAb (10 μg, ∼study day 7) assessed using flow cytometry (nonspecific binding was blocked with human or mouse Fc block). Each symbol represents an individual mouse. <b>D–F,</b> A549 (subcutaneous) tumor-bearing NSG mice were administered intraperitoneally biweekly with feladilimab or isotype control for a total of six doses. <b>D,</b> A549 tumor growth kinetics for controls (PBS or isotype) and feladilimab-treated groups (0.04 mg/kg, black; 0.4 mg/kg, red). Percentage of tumor-infiltrating ICOS+ CD8⁺ T cells (<b>E</b>; assessed using flow cytometry with nonspecific binding blocked using human or mouse Fc block) and associated CD8:T_reg cell ratio (<b>F</b>) 48 hours after the fourth dose of feladilimab (∼study day 21). Data in C, D, E, and F represent the mean ± s.e.m. Significance was determined by unpaired Student <i>t</i> test. See <a href=#SMF1 target=_blank>Supplementary Fig. S1</a> for flow cytometry gating strategy for C, E, and F. CD8/Treg ratios were calculated on the basis of percent (%) positive CD8s (of live CD45⁺) and FoxP3/CD25⁺ Treg cells (of live CD45⁺ CD4⁺ cells). ICOS, inducible T-cell costimulator; i.p., intraperitoneal injection; mAb, monoclonal antibody; OS, overall survival; s.e.m., standard error of the mean.</p>" @default.
• W4385877462 created "2023-08-17" @default.
• W4385877462 creator A5000219610 @default.
• W4385877462 creator A5001962000 @default.
• W4385877462 creator A5004021303 @default.
• W4385877462 creator A5004072228 @default.
• W4385877462 creator A5015114773 @default.
• W4385877462 creator A5015668076 @default.
• W4385877462 creator A5018536695 @default.
• W4385877462 creator A5022516918 @default.
• W4385877462 creator A5026700573 @default.
• W4385877462 creator A5027408575 @default.
• W4385877462 creator A5027768129 @default.
• W4385877462 creator A5029679351 @default.
• W4385877462 creator A5038356599 @default.
• W4385877462 creator A5038887077 @default.
• W4385877462 creator A5039345673 @default.
• W4385877462 creator A5045119909 @default.
• W4385877462 creator A5046901107 @default.
• W4385877462 creator A5049176429 @default.
• W4385877462 creator A5053416448 @default.
• W4385877462 creator A5059006181 @default.
• W4385877462 creator A5059747154 @default.
• W4385877462 creator A5060469120 @default.
• W4385877462 creator A5060590115 @default.
• W4385877462 creator A5062799755 @default.
• W4385877462 creator A5062921585 @default.
• W4385877462 creator A5063142060 @default.
• W4385877462 creator A5069580658 @default.
• W4385877462 creator A5073127295 @default.
• W4385877462 creator A5076409863 @default.
• W4385877462 creator A5085886223 @default.
• W4385877462 creator A5086481435 @default.
• W4385877462 creator A5088225387 @default.
• W4385877462 creator A5092500927 @default.
• W4385877462 creator A5092501397 @default.
• W4385877462 creator A5092501818 @default.
• W4385877462 date "2023-08-16" @default.
• W4385877462 modified "2023-09-27" @default.
• W4385877462 title "FIGURE 3 from Activating Inducible T-cell Costimulator Yields Antitumor Activity Alone and in Combination with Anti-PD-1 Checkpoint Blockade" @default.
• W4385877462 doi "https://doi.org/10.1158/2767-9764.23968505" @default.
• W4385877462 hasPublicationYear "2023" @default.
• W4385877462 type Work @default.
• W4385877462 citedByCount "0" @default.
• W4385877462 crossrefType "posted-content" @default.
• W4385877462 hasAuthorship W4385877462A5000219610 @default.
• W4385877462 hasAuthorship W4385877462A5001962000 @default.
• W4385877462 hasAuthorship W4385877462A5004021303 @default.
• W4385877462 hasAuthorship W4385877462A5004072228 @default.
• W4385877462 hasAuthorship W4385877462A5015114773 @default.
• W4385877462 hasAuthorship W4385877462A5015668076 @default.
• W4385877462 hasAuthorship W4385877462A5018536695 @default.
• W4385877462 hasAuthorship W4385877462A5022516918 @default.
• W4385877462 hasAuthorship W4385877462A5026700573 @default.
• W4385877462 hasAuthorship W4385877462A5027408575 @default.
• W4385877462 hasAuthorship W4385877462A5027768129 @default.
• W4385877462 hasAuthorship W4385877462A5029679351 @default.
• W4385877462 hasAuthorship W4385877462A5038356599 @default.
• W4385877462 hasAuthorship W4385877462A5038887077 @default.
• W4385877462 hasAuthorship W4385877462A5039345673 @default.
• W4385877462 hasAuthorship W4385877462A5045119909 @default.
• W4385877462 hasAuthorship W4385877462A5046901107 @default.
• W4385877462 hasAuthorship W4385877462A5049176429 @default.
• W4385877462 hasAuthorship W4385877462A5053416448 @default.
• W4385877462 hasAuthorship W4385877462A5059006181 @default.
• W4385877462 hasAuthorship W4385877462A5059747154 @default.
• W4385877462 hasAuthorship W4385877462A5060469120 @default.
• W4385877462 hasAuthorship W4385877462A5060590115 @default.
• W4385877462 hasAuthorship W4385877462A5062799755 @default.
• W4385877462 hasAuthorship W4385877462A5062921585 @default.
• W4385877462 hasAuthorship W4385877462A5063142060 @default.
• W4385877462 hasAuthorship W4385877462A5069580658 @default.
• W4385877462 hasAuthorship W4385877462A5073127295 @default.
• W4385877462 hasAuthorship W4385877462A5076409863 @default.
• W4385877462 hasAuthorship W4385877462A5085886223 @default.
• W4385877462 hasAuthorship W4385877462A5086481435 @default.
• W4385877462 hasAuthorship W4385877462A5088225387 @default.
• W4385877462 hasAuthorship W4385877462A5092500927 @default.
• W4385877462 hasAuthorship W4385877462A5092501397 @default.
• W4385877462 hasAuthorship W4385877462A5092501818 @default.
• W4385877462 hasBestOaLocation W43858774621 @default.
• W4385877462 hasConcept C126322002 @default.
• W4385877462 hasConcept C153911025 @default.
• W4385877462 hasConcept C159654299 @default.
• W4385877462 hasConcept C167672396 @default.
• W4385877462 hasConcept C170493617 @default.
• W4385877462 hasConcept C185592680 @default.
• W4385877462 hasConcept C203014093 @default.
• W4385877462 hasConcept C2776090121 @default.
• W4385877462 hasConcept C2777991845 @default.
• W4385877462 hasConcept C2778453870 @default.
• W4385877462 hasConcept C2778468042 @default.
• W4385877462 hasConcept C542903549 @default.
• W4385877462 hasConcept C71924100 @default.
• W4385877462 hasConcept C86803240 @default.
• W4385877462 hasConcept C8891405 @default.
• W4385877462 hasConceptScore W4385877462C126322002 @default.
• W4385877462 hasConceptScore W4385877462C153911025 @default.
• W4385877462 hasConceptScore W4385877462C159654299 @default.
• W4385877462 hasConceptScore W4385877462C167672396 @default.

• next